Abingworth
UK-founded international biotech VC; participated in Cytospire's £61m Series A.
Last refreshed: 13 May 2026 · Appears in 1 active topic
Timeline for Abingworth
Cytospire's £61m oncology Series A oversubscribed
UK Startups and Innovation- What is Abingworth and what do they invest in?
- Abingworth is a London- and Boston-based biotech VC founded in 1973, focusing on clinical-stage drug development in oncology, immunology, and rare disease.Source: Abingworth
- Who invested in Cytospire's Series A?
- Cytospire's £61m Series A was backed by Abingworth, Servier Ventures, Sound Bioventures, LifeArc Ventures, and Medical Incubator Japan.Source: Lowdown uk-startups-and-innovation U#4
- Is Abingworth one of the oldest UK biotech VCs?
- Yes. Abingworth was founded in 1973, making it one of the longest-established dedicated life-sciences venture capital firms in the UK.Source: Abingworth
Background
Abingworth participated in Cytospire's £61m Series A in May 2026, one of a syndicate including Servier Ventures, Sound Bioventures, LifeArc Ventures, and Medical Incubator Japan. Cytospire is developing CYT X300, a pan-gamma delta T cell engager for solid tumours.
Abingworth is a London- and Boston-based biotech venture capital firm founded in 1973, one of the oldest dedicated life-sciences VC firms in the UK. It focuses on clinical-stage drug development across oncology, immunology, and rare disease, with a transatlantic model investing in both UK/European and US biotech. Its portfolio spans companies from pre-clinical through to public-market crossover. Abingworth is known for scientifically rigorous diligence and long-hold-period conviction bets.